This funding opportunity supports clinical research studies of Atirmociclib targeting HR+/HER2- and/or HER2+ breast cancer. Research can be conducted across multiple countries globally, focusing on advancing treatment options in oncology.
Eligibility criteria are not specified for this funding opportunity.
